EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Efficacy and safety of varenicline nasal spray in dry eye disease: a systematic review and meta-analysis of randomized controlled trials

Sara Almutawtah, Yaqoub AlFoudari, Ahmed Mohammad, Shahad T Ahmad, Shooq Hussain Alanezi, Farah R Alqussair, Abdulrahman Alfailakawi, Haidar Bonajmah, Abdullah M Alharran iD

International Ophthalmology · 21.07.2026 · 46 (1)

DOI: 10.1007/s10792-026-04178-5 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift International Ophthalmology, online erschienen am 21.07.2026. Verfasst von Sara Almutawtah und 8 weiteren Autor:innen. Beteiligte Einrichtung: Kuwait Institute for Medical Specialization, Kuwait City, Al Asimah, Kuwait. Hauptthemen laut MEDLINE: Varenicline, Randomized Controlled Trials as Topic, Dry Eye Syndromes. Die Arbeit nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Dry eye disease is a multifactorial ocular surface disorder characterized by tear film instability and inflammation, leading to impaired visual function and reduced quality of life. Varenicline solution nasal spray is a nicotinic acetylcholine receptor agonist stimulates the trigeminal pathway to enhance basal tear production. METHODS: We searched electronic databases (PubMed, Scopus, and Web of Science) from inception to February 2026 to identify randomized controlled trials (RCTs) assessing varenicline nasal spray (0.03 mg or 0.06 mg twice daily) in adults with dry eye symptoms. Primary outcomes included the proportion of patients achieving ≥ 10-mm improvement in Schirmer test score (STS) and mean change in STS. Secondary outcomes included Eye Dryness Score (EDS), corneal fluorescein staining and treatment-emergent adverse events (TEAEs). Meta-analyses were conducted using random-effects models. The primary analysis focused on the approved 0.06 mg dose, with dose-based subgroup analyses comparing 0.03 mg and 0.06 mg doses where data were available. RESULTS: Seven randomized controlled trials were included. In the primary 0.06 mg analysis, varenicline nasal spray significantly improved mean Schirmer test score change (MD = 5.52 mm; 95% CI: 4.08 to 6.97; p < 0.0001) and increased the proportion of patients achieving a ≥ 10-mm Schirmer test score improvement (RR = 1.86; 95% CI: 1.50 to 2.30; p < 0.0001). Eye Dryness Score showed a non-significant numerical improvement (MD = - 4.38; 95% CI: - 12.02 to 3.25; p = 0.2601). Dose-based subgroup analyses showed consistent Schirmer test benefits for both 0.03 mg and 0.06 mg doses. Corneal fluorescein staining was not significantly improved. Ocular adverse events and reduced visual acuity were comparable between groups, while non-ocular adverse events, particularly sneezing, were more frequent with varenicline. CONCLUSIONS: Varenicline nasal spray improved tear production, with less consistent effects on symptoms and corneal staining. Ocular safety was comparable, but sneezing was more frequent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VareniclineRandomized Controlled Trials as TopicDry Eye SyndromesHumansNasal SpraysNicotinic AgonistsTreatment OutcomeTears

Stichwörter der Autor:innen

Dry eye diseaseNasal spraySchirmer testTear productionVarenicline

Substanzen

VareniclineNasal SpraysNicotinic Agonists

Autor:innen und Institutionen

  • Kuwait Institute for Medical Specialization, Kuwait City, Al Asimah, Kuwait.
  • College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.
  • Royal College of Surgeons in Ireland, Dublin, Ireland.
  • College of Medicine and Medical Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain. Dr_alharran@outlook.com.

ORCID-Profile: Abdullah M Alharran

Zitieren

APA

Almutawtah, S., AlFoudari, Y., Mohammad, A., Ahmad, S. T., Alanezi, S. H., Alqussair, F. R., Alfailakawi, A., Bonajmah, H., & Alharran, A. M. (2026). Efficacy and safety of varenicline nasal spray in dry eye disease: a systematic review and meta-analysis of randomized controlled trials. International Ophthalmology, 46(1). https://doi.org/10.1007/s10792-026-04178-5

Vancouver

Almutawtah S, AlFoudari Y, Mohammad A, Ahmad ST, Alanezi SH, Alqussair FR, et al. Efficacy and safety of varenicline nasal spray in dry eye disease: a systematic review and meta-analysis of randomized controlled trials. International Ophthalmology. 2026;46(1). doi:10.1007/s10792-026-04178-5

BibTeX
@article{Almutawtah2026,
  author = {Almutawtah, Sara and AlFoudari, Yaqoub and Mohammad, Ahmed and Ahmad, Shahad T and Alanezi, Shooq Hussain and Alqussair, Farah R and Alfailakawi, Abdulrahman and Bonajmah, Haidar and Alharran, Abdullah M},
  title = {Efficacy and safety of varenicline nasal spray in dry eye disease: a systematic review and meta-analysis of randomized controlled trials},
  journal = {International Ophthalmology},
  year = {2026},
  volume = {46},
  number = {1},
  doi = {10.1007/s10792-026-04178-5}
}
Kostenlos starten →